Equities

Psychemedics Corp

PMD:NAQ

Psychemedics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.34
  • Today's Change0.01 / 0.43%
  • Shares traded82.46k
  • 1 Year change-37.27%
  • Beta0.6809
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.

  • Revenue in USD (TTM)20.79m
  • Net income in USD-4.56m
  • Incorporated1986
  • Employees116.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kindly MD Inc3.10m-2.44m7.14m23.00--1.63--2.30-0.4652-0.46520.57430.73760.98675.94471.36134,643.90-77.81---99.26--93.94---78.86--5.36-5.610.0517---0.488--36.34------
Interpace Biosciences Inc41.68m3.00m7.37m108.002.49--2.150.17680.6740.63029.46-2.852.8814.197.10385,888.9020.72-38.19---69.7359.0149.447.19-41.010.46954.95----26.3112.93118.96--0.9184--
Mangoceuticals Inc866.79k-9.13m7.48m----0.5267--8.63-0.4388-0.43880.0410.47470.093519.32-----98.48---107.62--58.19---1,052.90--0.3653-38.860.0134--8,082.22---361.07------
Caremax Inc784.55m-782.86m7.74m1.45k------0.0099-208.41-208.41208.34-38.730.9776--6.10541,069.60-97.55---160.21---3.31---99.78-----1.951.57--19.01---1,707.99------
US NeuroSurgical Holdings Inc0.00-1.02m8.77m2.00--4.39-----0.0928-0.09280.000.14820.00----0.00-45.80-14.62-66.91-19.89-------36.77----0.00------38.97------
Aesthetic Medical Intl Hldg Grp Ltd(ADR)103.07m-6.87m8.98m1.29k--2.274.420.0872-0.1524-0.15242.270.08271.2920.8277.3680,144.66-9.06-23.36-35.45-48.5845.3955.32-7.02-23.720.2031-5.500.9581--1.86-2.1650.91--3.70--
Xcelerate Inc3.96m-296.19k9.21m1.00--6.62--2.33-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Ontrak Inc12.39m-36.52m10.03m102.00--0.6504--0.8095-2.35-2.350.30570.32130.5173--12.53121,421.60-115.11-54.80-157.11-73.3766.8153.50-222.54-71.95---1.730.3021---12.20-3.4439.08--99.58--
Streamline Health Solutions Inc20.30m-18.82m10.70m77.00--0.673--0.5272-0.3277-0.32770.34990.25110.4397--7.64263,636.40-40.77-22.06-56.63-31.6950.8649.96-92.72-54.55---4.460.4395---9.210.2057-64.31---11.72--
Pacific Health Care Organization Inc6.02m873.35k10.87m30.0012.460.969411.941.810.06820.06820.46930.87630.5208--6.67200,501.307.567.298.107.8178.9782.7514.5213.28----0.00---2.00-3.7055.80-10.80-15.93--
Univec Inc-100.00bn-100.00bn11.86m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Healthlynked Corp4.06m-4.38m12.12m38.00------2.98-0.0158-0.01590.0148-0.00150.865915.3340.39106,922.10-93.24-119.37-327.73-332.2252.3155.81-107.68-119.260.5622--2.15---2.3220.4357.08---12.94--
Psychemedics Corp.20.79m-4.56m13.63m116.00--2.37--0.6556-0.7882-0.78823.590.98581.57--5.89179,198.30-34.41-7.44-53.29-9.7037.6337.55-21.93-6.26---264.690.1198---12.45-12.33-283.21---33.32--
PharmChem Inc5.98m1.14m16.82m170.0015.006.1314.752.810.24140.24141.260.59031.839.258.71--34.87--42.91--64.49--19.05--5.20--0.00--3.50---16.95------
Data as of Sep 20 2024. Currency figures normalised to Psychemedics Corp's reporting currency: US Dollar USD

Institutional shareholders

19.51%Per cent of shares held by top holders
HolderShares% Held
22NW LPas of 30 Jun 2024274.42k4.71%
Renaissance Technologies LLCas of 30 Jun 2024256.96k4.41%
The Vanguard Group, Inc.as of 30 Jun 2024251.28k4.32%
RBF Capital LLCas of 30 Jun 2024142.14k2.44%
BlackRock Fund Advisorsas of 30 Jun 202470.61k1.21%
Wedbush Securities, Inc. (Investment Management)as of 30 Jun 202450.34k0.86%
Geode Capital Management LLCas of 30 Jun 202437.21k0.64%
SMP Asset Management LLCas of 30 Jun 202420.00k0.34%
Dimensional Fund Advisors LPas of 30 Jun 202417.75k0.31%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202415.24k0.26%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.